Research Article
Association between Fluorescent Advanced Glycation End-Products and Vascular Complications in Type 2 Diabetic Patients
Table 1
Clinical and biochemical characteristics of the study participants.
| | | | |
| | | | | Male Sex (%) | | | | With vascular complication | | | |
| | Average +/− SD | Average +/− SD | value | Age | 51.2 +/− 17.7 | 59.1 +/− 10.3 | 0.0164 | BMI | | 30.2 +/− 5.5 | | Total protein (g/L) | 69.8 +/− 6.3 | 70.6 +/− 4.5 | 0.5201 | Albumin (g/L) | 40.5 +/− 7.1 | 42.3 +/− 2.8 | <0.0001 | Fructosamine (mol/g) | 2.67 +/− 0.41 | 4.78 +/− 0.77 | <0.0001 | HbA1c (%) | 5.3 +/− 0.43 | 9.1 +/− 1.1 | <0.0001 | Total cholesterol (mmol/L) | 4.4 +/− 0.82 | 4.14 +/− 1.04 | 0.2488 | HDL-cholesterol (mmol/L) | 1.27 +/− 0.44 | 1.12 +/− 0.29 | 0.0771 | LDL-cholesterol (mmol/L) | 2.82 +/− 0.75 | 2.50 +/− 0.90 | 0.1079 | Triglycerides (mmol) | | | 0.67 | (25–75th percentile) | | | | ApoA (mmol/L) | 1.42 +/− 0.37 | 1.30 +/− 0.22 | | ApoB (mmol/L) | 0.84 +/− 0.16 | 0.89 +/− 0.25 | |
|
|
Study participants are divided into two groups: diabetic (D, ) and nondiabetic (ND, ) patients.
|